Real-world clinico-genomic evidence can fill knowledge gaps and identify unmet needs for patients with lung cancer
Harnessing the power of RWE across the NSCLC drug development lifecycle
Research Goal: Trial eligibility criteria and diversity among patients with advanced NSCLC